• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
ATRA+ATO combination in APL - A commentary on "evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades" by Teng-Fei et al.全反式维甲酸与三氧化二砷联合治疗急性早幼粒细胞白血病——对滕飞等人《急性早幼粒细胞白血病治疗模式的演变与挑战：过去三十年1105例患者的真实世界分析》的述评
Transl Oncol. 2023 Mar;29:101620. doi: 10.1016/j.tranon.2023.101620. Epub 2023 Jan 10.
2
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.全反式维甲酸和三氧化二砷治疗急性早幼粒细胞白血病：协同分子靶向治疗的范例
Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71. doi: 10.1098/rstb.2007.2026.
3
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.Src 家族激酶抑制剂 PP2 增强全反式维甲酸和三氧化二砷联合诱导的急性早幼粒细胞白血病细胞系的分化。
Leuk Res. 2014 Aug;38(8):977-82. doi: 10.1016/j.leukres.2014.05.019. Epub 2014 Jun 4.
4
Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.三氧化二砷与全反式维甲酸（ATRA）治疗所有风险组急性早幼粒细胞白血病：一项随机对照试验的研究方案
Trials. 2018 Sep 5;19(1):476. doi: 10.1186/s13063-018-2812-3.
5
Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.阿糖胞苷在全反式维甲酸和三氧化二砷联合治疗儿童急性早幼粒细胞白血病中的作用：一项随机对照试验。
BMC Cancer. 2018 Apr 3;18(1):374. doi: 10.1186/s12885-018-4280-2.
6
Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.全反式维甲酸和三氧化二砷治疗急性早幼粒细胞白血病时的白细胞增多。
Br J Haematol. 2024 Nov;205(5):1672-1673. doi: 10.1111/bjh.19763. Epub 2024 Sep 15.
7
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.三氧化二砷单药或联合全反式维甲酸用于非高危急性早幼粒细胞白血病诱导治疗的比较
Leuk Res. 2018 Mar;66:85-88. doi: 10.1016/j.leukres.2018.01.019. Epub 2018 Feb 3.
8
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病：一项系统评价与荟萃分析
Zhong Xi Yi Jie He Xue Bao. 2009 Nov;7(11):1024-34. doi: 10.3736/jcim20091102.
9
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.全反式维甲酸和三氧化二砷无法解除急性早幼粒细胞白血病细胞中单核细胞分化驱动因子Irf8的抑制状态。
Cell Death Dis. 2017 May 11;8(5):e2782. doi: 10.1038/cddis.2017.197.
10
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.全反式维甲酸联合三氧化二砷治疗急性早幼粒细胞白血病的荟萃分析。
Hematology. 2014 Jun;19(4):202-7. doi: 10.1179/1607845413Y.0000000118. Epub 2013 Nov 25.

本文引用的文献

1
Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades.急性早幼粒细胞白血病治疗模式的演变及挑战：过去三十年1105例患者的真实世界分析
Transl Oncol. 2022 Nov;25:101522. doi: 10.1016/j.tranon.2022.101522. Epub 2022 Sep 5.
2
Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study.全反式维甲酸联合砷剂时代急性早幼粒细胞白血病患者的早期死亡与生存：一项基于人群的研究
Front Oncol. 2021 Nov 16;11:762653. doi: 10.3389/fonc.2021.762653. eCollection 2021.
3
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.美国急性早幼粒细胞白血病患者的治疗模式和实际临床结局。
Blood Adv. 2022 Jan 25;6(2):376-385. doi: 10.1182/bloodadvances.2021005642.
4
Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia.基因组和转录组标志物的整合提高了急性早幼粒细胞白血病的预后预测。
Clin Cancer Res. 2021 Jul 1;27(13):3683-3694. doi: 10.1158/1078-0432.CCR-20-4375. Epub 2021 Apr 23.
5
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Cancer. 2020 Jan 15;126(2):256-259. doi: 10.1002/cncr.32608. Epub 2019 Nov 12.
6
Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012.急性早幼粒细胞白血病在巴西急性髓系白血病中极为常见：一项基于2001年至2012年医院的癌症登记研究。
Ann Hematol. 2017 Mar;96(3):355-362. doi: 10.1007/s00277-016-2846-0. Epub 2016 Oct 18.
7
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.美国使用三氧化二砷和维甲酸治疗急性早幼粒细胞白血病患者的成本效益分析
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):771-7. doi: 10.1016/j.clml.2015.07.634. Epub 2015 Aug 5.
8
Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California.加利福尼亚州急性早幼粒细胞白血病儿童、青少年及年轻成年人的早期死亡和生存差异。
Cancer. 2015 Nov 15;121(22):3990-7. doi: 10.1002/cncr.29631. Epub 2015 Aug 11.
9
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.口服砷剂和维甲酸治疗非高危急性早幼粒细胞白血病。
N Engl J Med. 2014 Dec 4;371(23):2239-41. doi: 10.1056/NEJMc1412035.
10
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.尽管采用全反式维甲酸治疗，但急性早幼粒细胞白血病的早期死亡率仍然很高。
Blood. 2011 Aug 4;118(5):1248-54. doi: 10.1182/blood-2011-04-346437. Epub 2011 Jun 8.

ATRA+ATO combination in APL - A commentary on "evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades" by Teng-Fei et al.

作者信息

Ortaboz Damla, Çetin Mehmed Semih, Cömert Burak, Eşkazan Ahmet Emre

机构信息

Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

出版信息

Transl Oncol. 2023 Mar;29:101620. doi: 10.1016/j.tranon.2023.101620. Epub 2023 Jan 10.

DOI:10.1016/j.tranon.2023.101620
PMID:36737174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9937804/
Abstract
摘要